Interpace Biosciences Inc.

8.00-0.2400-2.91%Vol 11.84K1Y Perf 34.76%
Apr 20th, 2021 15:59 DELAYED
BID0.0000 ASK0.0000
Open8.29 Previous Close8.24
Pre-Market- After-Market7.81
 - -  -0.19 -2.38%
Target Price
10.50 
Analyst Rating
Strong Buy 1.00
Potential %
31.25 
Finscreener Ranking
★★     46.90
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     39.45
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     44.72
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap32.90M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
91.57 
Earnings Date
28th Apr 2021

Today's Price Range

7.768.29

52W Range

2.578.50

5 Year PE Ratio Range

-1.80-1.50

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-2.56%
1 Month
52.38%
3 Months
90.93%
6 Months
133.24%
1 Year
34.76%
3 Years
-12.09%
5 Years
-82.22%
10 Years
-99.07%

TickerPriceChg.Chg.%
IDXG8.00-0.2400-2.91
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Financial StrengthValueIndustryS&P 500US Markets
0.60
0.80
0.81
5.12
-46.60
Leverage Ratio -4.80
ProfitabilityValueIndustryS&P 500US Markets
33.10
-79.00
-62.00
-110.20
-86.72
RevenueValueIndustryS&P 500US Markets
23.20M
5.64
22.16
20.99
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.32-2.00-51.52
Q03 2020--1.53-
Q02 2020--1.35-
Q01 2020-1.19-2.31-94.12
Q04 2019--2.61-
Q03 2019-0.90-1.70-88.89
Q02 2019-0.60-1.10-83.33
Q01 2019-0.70-1.00-42.86
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.43-70.24Negative
6/2021 QR-1.01-65.57Negative
12/2021 FY-3.16-114.97Negative
12/2021 FY-1.62-10.20Negative
Next Report Date28th Apr 2021
Estimated EPS Next Report-1.32
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume11.84K
Shares Outstanding4.11M
Trades Count82
Dollar Volume644.71K
Avg. Volume164.33K
Avg. Weekly Volume19.98K
Avg. Monthly Volume53.39K
Avg. Quarterly Volume160.67K

Interpace Biosciences Inc. (NASDAQ: IDXG) stock closed at 8 per share at the end of the most recent trading day (a -2.91% change compared to the prior day closing price) with a volume of 12.00K shares and market capitalization of 32.90M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 178 people. Interpace Biosciences Inc. CEO is Thomas Burnell.

The one-year performance of Interpace Biosciences Inc. stock is 34.76%, while year-to-date (YTD) performance is 154.78%. IDXG stock has a five-year performance of -82.22%. Its 52-week range is between 2.5721 and 8.5, which gives IDXG stock a 52-week price range ratio of 91.57%

Interpace Biosciences Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 10.04, a price-to-sale (PS) ratio of 1.46, a price to cashflow ratio of 48.50, a PEG ratio of 2.32, a ROA of -57.93%, a ROC of -433.04% and a ROE of 173.64%. The company’s profit margin is -86.72%, its EBITDA margin is -62.00%, and its revenue ttm is $23.20 Million , which makes it $5.64 revenue per share.

Of the last four earnings reports from Interpace Biosciences Inc., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.32 for the next earnings report. Interpace Biosciences Inc.’s next earnings report date is 28th Apr 2021.

The consensus rating of Wall Street analysts for Interpace Biosciences Inc. is Strong Buy (1), with a target price of $10.5, which is +31.25% compared to the current price. The earnings rating for Interpace Biosciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Interpace Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Interpace Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.55, ATR14 : 0.64, CCI20 : 82.16, Chaikin Money Flow : 0.46, MACD : 0.99, Money Flow Index : 85.64, ROC : 73.66, RSI : 52.88, STOCH (14,3) : 93.32, STOCH RSI : 0.84, UO : 64.99, Williams %R : -6.68), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Interpace Biosciences Inc. in the last 12-months were: James Early (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Interpace Biosciences Inc.

Interpace Biosciences Inc is a growing leader in the life sciences industry. It provides complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics. The activities of the company are functioned through two business units. The Interpace Diagnostics business unit which provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services and Interpace Pharma Solutions business supports clinical trials by providing lab testing, data management, project management, and biorepository services to biopharmaceutical companies.

CEO: Thomas Burnell

Telephone: +1 855 776-6419

Address: 300 Interpace Parkway, Parsippany 07054, NJ, US

Number of employees: 178

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

53%47%

Bearish Bullish

56%44%

Bearish Bullish

60%40%

News

Stocktwits